Cosentyx Secukinumab Application Scope

Cosentyx® is a fully human monoclonal antibody targeting interleukin-17A (IL-17A), approved for treating immune-mediated inflammatory conditions, including moderate to severe plaque psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), enthesitis-related arthritis (ERA), juvenile psoriatic arthritis (JPsA), and hidradenitis suppurativa (HS).

Cosentyx Secukinumab Characteristics

Ingredients: Secukinumab
Properties: White to off-white lyophilized powder for solution for injection or clear to opalescent, colorless to slightly yellow solution.
Packaging Specification: Prefilled syringe or prefilled pen containing 150 mg/mL; available in single-unit or multipack cartons.
Storage: Store in a refrigerator at 2 °C – 8 °C. Do not freeze. Keep in the original package to protect from light.
Expiry Date: 24 months from the date of manufacture.
Executive Standard: Manufacturer’s internal quality standards in compliance with EMA/FDA specifications.
Approval Number: Refer to the corresponding national drug approval code.
Date of Revision: [Insert latest revision date here]
Manufacturer: Novartis Pharma AG, Switzerland

Guidelines for the Use of Cosentyx Secukinumab

Dosage & Administration

Plaque Psoriasis (Adults ≥18 y/o): 300 mg SC at weeks 0, 1, 2, 3, 4, then every 4 weeks; some patients may use 150 mg
Psoriatic Arthritis (PsA):
- With loading: 150 mg at weeks 0–4, then monthly; if inadequate, consider 300 mg monthly
Ankylosing Spondylitis (AS) / nr-axSpA: Similar to PsA pattern
Hidradenitis Suppurativa (HS): 300 mg SC at weeks 0–4, then monthly; may increase to every 2 weeks if needed
ERA & JPsA (Pediatric ≥4 or ≥2 y/o respectively): Weight-based dosing: 75 mg (<50 kg) or 150 mg (≥50 kg), weekly for 5 weeks, then monthly

Adverse Reactions
- Common (≥10%): Upper respiratory tract infections; injection site reactions uncommon (~1.9%)
- Other Common: Oral herpes, diarrhea, runny nose
- Serious: Inflammatory bowel disease exacerbation, serious infections; hypersensitivity reactions rare
Contraindications: Prior serious hypersensitivity to secukinumab or components.
Precautions: Monitor for infections, especially IBD flares; use caution in patients with chronic infection; pregnancy only if risk-benefit justifies .

Cosentyx Secukinumab Interactions

No major drug interactions reported; no known CYP metabolism issues.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.